Datapoint: Latest Patent Ruling Protects Imbruvica Until 2032

AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Pharma began in 2019. Imbruvica, which launched in 2014, is approved to treat several cancers, including chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. Under the pharmacy benefit, Imbruvica holds covered or better status for 71% of all insured lives.

SOURCE: MMIT Analytics, as of 9/1/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today